Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

Table of Contents

April 01, 2002; Volume 69,Issue 4 suppl 1

Coxibs: Evolution of a Revolutionary Class: Evolving Concepts and Issues Surrounding COX-2 Inhibitors

Preface

  • You have access
    Preface
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-3;

Foreword

  • You have access
    Foreword
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-3-SI-4;

Article

  • You have access
    Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
    Clifton O. Bingham, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-5-SI-12;
  • You have access
    Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility
    Bruce N. Cronstein, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-13-SI-19;
  • You have access
    COX-2–selective inhibitors in the treatment of arthritis
    Thomas J. Schnitzer, MD, PhD and Marc C. Hochberg, MD, MPH
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-20-SI-30;
  • You have access
    Gastrointestinal safety and tolerability of non-selective non-steroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors
    David A. Peura, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-31-SI-39;
  • You have access
    Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors
    James M. Scheiman, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-40-SI-46;
  • You have access
    Current perspective on the cardiovascular effects of coxibs
    Marvin A. Konstam, MD and Matthew R. Weir, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-47-SI-52;
  • You have access
    Renal effects of nonselective NSAIDs and coxibs
    Matthew R. Weir, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-53-SI-58;
  • You have access
    Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy
    A. Mark Fendrick, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-59-SI-64;
  • You have access
    Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain
    Warren A. Katz, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-65-SI-75;
  • You have access
    Emerging options with coxib therapy
    Mark J. Lema, MD, PhD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-76-SI-84;
Back to top
PreviousNext

In this issue

Cleveland Clinic Journal of Medicine: 69 (4 suppl 1)
Cleveland Clinic Journal of Medicine
Vol. 69, Issue 4 suppl 1
1 Apr 2002
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Sign up for alerts

Jump to

  • Preface
  • Foreword
  • Article
  • Editor's Picks
  • Most Cited
  • Most Read
Loading
Do all patients with primary pulmonary coccidioidomycosis need antifungal therapy?
The double-tongue sign
Is exercise restriction necessary in patients with pericarditis?
Which ICU patients need stress ulcer prophylaxis?
Dactylitis from Mycobacterium intracellulare infection
Mondor disease of the breast
Dyspnea and cough in a lung transplant recipient
Atypical erythema as a clinical presentation of tinea incognito
Pigmented lesion on nail bed: Pseudo-Hutchinson sign
Hampton hump in acute pulmonary embolism
A brownish erythematous patch in the nipple-areola complex
The underappreciated role of documentation in improving COPD care
Oral hyperpigmentation with weakness and salt-craving
Glycemic targets in the ICU: A look back, and ahead

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2022 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire